Exagen Statistics
Total Valuation
Exagen has a market cap or net worth of $64.46 million. The enterprise value is $59.91 million.
Important Dates
The last earnings date was Tuesday, March 10, 2026, before market open.
| Earnings Date | Mar 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Exagen has 24.05 million shares outstanding. The number of shares has increased by 18.43% in one year.
| Current Share Class | 24.05M |
| Shares Outstanding | 24.05M |
| Shares Change (YoY) | +18.43% |
| Shares Change (QoQ) | +2.77% |
| Owned by Insiders (%) | 13.74% |
| Owned by Institutions (%) | 49.12% |
| Float | 16.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.97 |
| Forward PS | 0.90 |
| PB Ratio | 3.52 |
| P/TBV Ratio | 3.69 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.90 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.45, with a Debt / Equity ratio of 1.59.
| Current Ratio | 3.45 |
| Quick Ratio | 3.04 |
| Debt / Equity | 1.59 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3.26 |
Financial Efficiency
Return on equity (ROE) is -147.85% and return on invested capital (ROIC) is -22.54%.
| Return on Equity (ROE) | -147.85% |
| Return on Assets (ROA) | -17.12% |
| Return on Invested Capital (ROIC) | -22.54% |
| Return on Capital Employed (ROCE) | -32.08% |
| Weighted Average Cost of Capital (WACC) | 14.02% |
| Revenue Per Employee | $302,614 |
| Profits Per Employee | -$90,686 |
| Employee Count | 220 |
| Asset Turnover | 1.30 |
| Inventory Turnover | 6.16 |
Taxes
In the past 12 months, Exagen has paid $51,000 in taxes.
| Income Tax | 51,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -36.94% in the last 52 weeks. The beta is 1.91, so Exagen's price volatility has been higher than the market average.
| Beta (5Y) | 1.91 |
| 52-Week Price Change | -36.94% |
| 50-Day Moving Average | 3.55 |
| 200-Day Moving Average | 7.36 |
| Relative Strength Index (RSI) | 31.72 |
| Average Volume (20 Days) | 326,235 |
Short Selling Information
The latest short interest is 1.14 million, so 4.75% of the outstanding shares have been sold short.
| Short Interest | 1.14M |
| Short Previous Month | 1.07M |
| Short % of Shares Out | 4.75% |
| Short % of Float | 7.07% |
| Short Ratio (days to cover) | 3.38 |
Income Statement
In the last 12 months, Exagen had revenue of $66.58 million and -$19.95 million in losses. Loss per share was -$0.93.
| Revenue | 66.58M |
| Gross Profit | 38.80M |
| Operating Income | -14.07M |
| Pretax Income | -19.90M |
| Net Income | -19.95M |
| EBITDA | -11.95M |
| EBIT | -14.07M |
| Loss Per Share | -$0.93 |
Full Income StatementBalance Sheet
The company has $32.22 million in cash and $27.67 million in debt, with a net cash position of $4.55 million or $0.19 per share.
| Cash & Cash Equivalents | 32.22M |
| Total Debt | 27.67M |
| Net Cash | 4.55M |
| Net Cash Per Share | $0.19 |
| Equity (Book Value) | 17.45M |
| Book Value Per Share | 0.76 |
| Working Capital | 34.73M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$13.63 million and capital expenditures -$641,000, giving a free cash flow of -$14.27 million.
| Operating Cash Flow | -13.63M |
| Capital Expenditures | -641,000 |
| Depreciation & Amortization | 2.12M |
| Net Borrowing | 2.88M |
| Free Cash Flow | -14.27M |
| FCF Per Share | -$0.59 |
Full Cash Flow StatementMargins
Gross margin is 58.28%, with operating and profit margins of -21.13% and -29.97%.
| Gross Margin | 58.28% |
| Operating Margin | -21.13% |
| Pretax Margin | -29.89% |
| Profit Margin | -29.97% |
| EBITDA Margin | -17.95% |
| EBIT Margin | -21.13% |
| FCF Margin | n/a |
Dividends & Yields
Exagen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -18.43% |
| Shareholder Yield | -18.43% |
| Earnings Yield | -30.95% |
| FCF Yield | -22.13% |
Analyst Forecast
The average price target for Exagen is $9.14, which is 241.05% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.14 |
| Price Target Difference | 241.05% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (5Y) | 10.50% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Exagen has an Altman Z-Score of -4.32 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.32 |
| Piotroski F-Score | 3 |
